Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil for Remimazolam Reversal in Gynecological Surgery
NCT05382806Completed
- Sponsor
- Konkuk University Medical Center
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Randomised, double-blind trial comparing Placebo Group with Flumazenil Group (2 arms). Primary endpoint: Incidence of Postoperative Nausea and Vomiting at 24 hours. Started Aug 2022; status: completed.
02
Drugs
flumazenil
Beyond the preview
Go deeper on NCT05382806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382806.